We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

7 hedge funds and large institutions have $287K invested in Phio Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

3.5% less ownership

Funds ownership: 9.1% → 5.6% (-3.5%)

30% less funds holding

Funds holding: 10 → 7 (-3)

73% less capital inflows, than outflows

Capital inflows: $113K | Capital outflows: $416K

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
7
Holders Change
-3
Holders Change %
-30%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SG Americas Securities
SG Americas Securities
New York
+$75.3K
2
Two Sigma Securities
Two Sigma Securities
New York
+$18.8K
3
Edmond de Rothschild Holding
Edmond de Rothschild Holding
Switzerland
+$9.41K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$9.41K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$325K
2
DRW Securities
DRW Securities
Illinois
-$37K
3
Virtu Financial
Virtu Financial
New York
-$23K
4
First Allied Advisory Services
First Allied Advisory Services
California
-$22K
5
Intellectus Partners
Intellectus Partners
California
-$9.41K

PHIO Hedge Fund Activity: Q3 2018 in Review

7 of the 4,392 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2018, worth a combined $287K — down 62% from $748K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of PHIO and 1 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 3 added.

The largest buyer was SG Americas Securities, adding an estimated $75.3K. The largest seller was Sabby Management, exiting entirely with an estimated $325K sold.

  • 7 institutional investors held Phio Pharmaceuticals (PHIO) as of Q3 2018, down from 10 in Q2 2018.
  • Funds reported $287K of Phio Pharmaceuticals stock for Q3 2018, down 62% quarter-over-quarter.
  • 1 fund opened new Phio Pharmaceuticals positions in Q3 2018 and 4 closed out, a net change of -3 holders.
  • The largest Phio Pharmaceuticals buyer in Q3 2018 was SG Americas Securities, an estimated $75.3K added.
  • The largest Phio Pharmaceuticals seller in Q3 2018 was Sabby Management, an estimated $325K sold.

Based on aggregated 13F filings for Q3 2018.